Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Si Yang

Showing results (801-810 of 839) with videos related to

Pageof 84
Sort By:
NPJ Precision Oncology|October 1, 2024
The role of TERT C228T and KDM6A alterations and TME in NMIBC treated with BCGQi-Dong Xia, Jian-Xuan Sun, Zhi-Peng Yao, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 15, 2017
Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levelsJing Li, Tian-Ying Zhang, Liu-Wei Song, et al.
Science Bulletin|January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trialSi-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
Journal of Nanobiotechnology|November 20, 2024
Mechanism of cold exposure delaying wound healing in miceFu-Xing-Zi Li, Jun-Jie Liu, Li-Min Lei, et al.
Journal of Nanobiotechnology|June 24, 2026
Cold exposure-induced loss of beneficial gut bacterial sEV is associated with the pathogenesis of bone loss through pyroptosis pathwayLi-Min Lei, Xiao Lin, Feng Xu, et al.
The Lancet. Oncology|December 14, 2011
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trialLei Chen, Chao-Su Hu, Xiao-Zhong Chen, et al.
Molecular Oncology|April 20, 2023
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapyHai-Yan Tu, Kai Yin, Xiaotian Zhao, et al.
The Lancet. Oncology|December 9, 2025
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 studyYi-Long Wu, Yu Yao, Jin-Ji Yang, et al.
Signal Transduction and Targeted Therapy|February 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trialWen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, et al.
Journal of Nanobiotechnology|June 23, 2024
Cold exposure-induced plasma exosomes impair bone mass by inhibiting autophagyLi-Min Lei, Fu-Xing-Zi Li, Xiao Lin, et al.
Pageof 84

Showing results (801-810 of 839) with videos related to

Sort By:
Pageof 84
NPJ Precision Oncology|October 1, 2024
The role of TERT C228T and KDM6A alterations and TME in NMIBC treated with BCGQi-Dong Xia, Jian-Xuan Sun, Zhi-Peng Yao, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 15, 2017
Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levelsJing Li, Tian-Ying Zhang, Liu-Wei Song, et al.
Science Bulletin|January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trialSi-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
Journal of Nanobiotechnology|November 20, 2024
Mechanism of cold exposure delaying wound healing in miceFu-Xing-Zi Li, Jun-Jie Liu, Li-Min Lei, et al.
Journal of Nanobiotechnology|June 24, 2026
Cold exposure-induced loss of beneficial gut bacterial sEV is associated with the pathogenesis of bone loss through pyroptosis pathwayLi-Min Lei, Xiao Lin, Feng Xu, et al.
The Lancet. Oncology|December 14, 2011
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trialLei Chen, Chao-Su Hu, Xiao-Zhong Chen, et al.
Molecular Oncology|April 20, 2023
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapyHai-Yan Tu, Kai Yin, Xiaotian Zhao, et al.
The Lancet. Oncology|December 9, 2025
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 studyYi-Long Wu, Yu Yao, Jin-Ji Yang, et al.
Signal Transduction and Targeted Therapy|February 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trialWen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, et al.
Journal of Nanobiotechnology|June 23, 2024
Cold exposure-induced plasma exosomes impair bone mass by inhibiting autophagyLi-Min Lei, Fu-Xing-Zi Li, Xiao Lin, et al.
Pageof 84